The FDA has approved Orlynvah, a new oral treatment for uncomplicated urinary tract infections (UTIs) in women who have limited options for effective antibiotic therapy.

The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections (uUTIs).

Different medical conditions, aging, and lifestyle habits can all contribute to these symptoms.When nondrug strategies fail ...

The treatment has been shown to be active against third generation cephalosporin-resistant Enterobacterales species. Orlynvah combines sulopenem etzadroxil, a penem antibacterial drug, and probenecid, ...

The Food and Drug Administration has approved Iterum Therapeutics' Orlynvah, the first drug of its kind, which is designed to ...

The company has 4 antibiotic medications available for UTI treatment. You can select the medication you prefer or let your Wisp medical provider decide for you. You can have your prescription sent ...

Nonantibiotic prophylactic options for UTIs such as methenamine hippurate remain significantly underutilized, especially for ...

On Friday, Iterum Therapeutics plc (NASDAQ:ITRM) received FDA approval for its Orlynvah (sulopenem etzadroxil and probenecid) ...

Urinary tract infections (UTIs) are a common type of bladder infection that often require antibiotic treatment. That said ... There aren't any over-the-counter (OTC) treatments that are proven to cure ...

While more prevalent in women ... infection treatment Since yeast infections are not bacterial by nature like UTIs, antibiotics are ineffective. Instead, you should use antifungal medication ...

Urinary tract infections are common, especially, though not exclusively, in women, and the risk generally increases with age.